





Archaeology drew Svante Pääbo to
science when he was a boy growing
up in Sweden. But the university
archaeology courses he took while still
in high school in Uppsala were “too
slow,” he says. So he matriculated in
medicine and finally landed in one of
the most technically demanding areas
of laboratory biology: immunology.
But he still secretly dug mummies.
While a graduate student at the
University of Uppsala, he begged an
East Berlin museum director to let
him take tissue samples from
Egyptian mummies and then, working
nights and weekends, managed
against all expectation to clone DNA
from them. “It has always been
Svante’s style to go through walls
scientifically,” says molecular
evolutionist Alan Cooper of the
University of Oxford. The result was a
single-author paper in Nature in 1985.
This publication caught the eye of
the late, great Allan Wilson at the
University of California at Berkeley, a
pioneer in studying anthropology and
evolution with molecular techniques,
and Wilson invited Pääbo to do a post-
doctoral stint. Pääbo was thus in a
perfect position when the polymerase
chain reaction (PCR) was developed
nearby. He was one of the first to
apply PCR successfully to ancient
DNA work and he quickly became
known as a meticulous lab worker, a
requirement because ancient human
DNA could be contaminated so easily
by DNA from the investigator.
At the same time, Pääbo
developed a distinctly Californian
personal style. He ran in the hills
above Berkeley, flouted authority
and wore florid Hawaiian shirts and
shorts in the lab.
As a next destination, no place
would seem a larger leap than
conservative, Catholic Bavaria.
Except, recalls Cooper, that the
University of Munich was willing to
bend its rules requiring prior
university teaching experience to get
Pääbo. Furthermore, Pääbo won a
Leibniz Prize, the most prestigious
and lucrative German award for
young investigators. Then, when
Pääbo found out that as the holder of
a chair at a German university, he
would be answerable only “to the
Minister of Education and to God,”
as Cooper puts it, Pääbo was sold. 
The move to Germany in 1989
presented no language problems for
Pääbo. He speaks German as well as
Swedish and English, and reads
Russian, French, Coptic, Latin and
hieroglyphics. Although his anti-
authoritarian bent does not always
extend to those who work for him —
he wins more arguments than he
loses in the lab — he has nonetheless
succeeded in fostering a laboratory
‘microclimate’ that is multicultural
and open-minded.
Pääbo walked through another
wall last year when he headed the
first scientific team to read the
sequence of a piece of DNA from a
Neanderthal. The data supported
the view that there was no mating of
Neanderthals with the ancestors of
modern humans and that their
lineage parted from ours some
550,000 years ago.The result,
dubbed by Science a “technical tour de
force,” was the first molecular
evidence in the long-running debate
over Neanderthal–human mixing.
Pääbo has become known as a
paragon of caution in the study of
ancient DNA. Some of his most
influential papers use chemical
techniques to set out the practical
constraints of what can be learned
from early DNA samples. One 1996
Science paper used a class of chemical
changes called ‘racemization’ in
amino acids in old samples to show
that DNA older than 100,000 years
was very unlikely to have been
reliably preserved.
This discovery has served to limit
Pääbo’s own work too. Curled up
around a chair in stocking feet in his
Munich office, Pääbo sighs and his
deep voice gets even deeper: “I
know it sounds depressing, but we
have reached a sort of limit” in the
work on Neanderthal DNA. “It
would require another technical
breakthrough of the order of PCR to
go back any further in time.” He
admits that his early dreams of doing
population genetics on ancient DNA
samples have been “quenched” by
laboratory reality.
On the heels of the publication of
the Neanderthal work in Cell last July
came the announcement that Pääbo
would move from the University of
Munich to a directorship at a new
Max Planck Institute for
Evolutionary Anthropology in the
eastern German city of Leipzig.
Pääbo is excited about the move
to Leipzig because he sees the
founding of the new Institute as a
unique opportunity to create a kind of
‘Grand Unified Theory’ of molecular
and behavioural primate evolution. It
is a dramatic next challenge for a
career that has already brought more
than its share of coups. The institute
will have a projected budget of
US$14.1 million and a staff of 250.
And it will offer state-of-the-art
primate facilities integrated with the
Leipzig Zoo, an especially remarkable
departure at a time when US primate
facilities are being reduced in size.
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But Pääbo’s own 25-person group
will not grow. Instead, at the age of
42, Pääbo seems to have reached a
point in his scientific development
when he realizes that his future
successes may result as much from
his choice of collaborators as from the
achievements of his own laboratory.
The other directors at the new
institute — a psychologist, a linguist,
a molecular anthropologist, a
primatologist and someone who
works on the interaction of genes and
culture — include some of the top
primate researchers and molecular
anthropologists in the world.
In the new institute, says Pääbo,
“we would like to do comparative
work on humans and other primates,
particularly humans and chimps.”
Only about 2% of our DNA is
different, but “what makes a chimp a
chimp and a human a human,” he
says, “may be due more to the
difference in expression of genes. No
one knows.”
The attempt is not without risks.
The Leipzig institute is itself a kind
of primate experiment, bringing
several driven scientists together and
asking them to do interdisciplinary
research, says Pääbo. “It’s a bit like
putting us in an enclosure to see if all
you get is alpha-male posturing or if
something constructive comes out.”




What is it famous for? Being the
world’s biggest medical research
charity. With total assets of more than
£8 billion and a research budget of
about £250 million a year, the
Wellcome Trust outflanks even the
Howard Hughes Medical Institute,
its closest counterpart in the US.
Beholden to no one and nothing
except the wishes of its founder, Sir
Henry Wellcome, the Trust
essentially does exactly what it likes
with its money to “support scientific
research which may conduce to the
improvement of the physical
conditions of mankind.” And as the
old man’s been dead for more than 60
years, that leaves plenty of scope.
Quite a big fish, then? You’ve said it.
The Trust itself is proud of its
freedom and independence, claiming
that it is able to fund high-risk
projects that others cannot and
boasting of its ability to react quickly
to changing needs — for example, its
decision to build the Sanger Centre
near Cambridge for genomic
sequencing. But some of the punters
find it high-handed and arrogant.
How did it all start? On the death of Sir
Henry in 1936. The share capital from
his pharmaceutical company, then
called the Wellcome Foundation, was
vested with trustees. The trustees
(now called governors) decide policy
and distribute income according to
the wishes laid down in his will. Sir
Henry allowed for partial sale of the
company in “special circumstances”,
and the present great wealth of the
Trust was generated when the trustees
took advantage of this caveat to float
the company on the stock market in
1986. More shares were sold in 1992.
The Wellcome Foundation was 
re-named Wellcome plc and then
merged with Glaxo in 1995 to
become Glaxo Wellcome.
Is the company still associated with the
Trust? The Trust has a 4.7% stake in
the pharmaceutical company, but the
two are entirely independent. 
So who are the all-powerful governors?
Nine “distinguished members of the
scientific and financial community,”
says the Trust. (Note the assumption
that scientists and financiers share a
common community.) These
distinguished persons (five of whom
have knighthoods) include two
financiers and seven academics — all
from ‘ivy-league’ institutions in
Oxford, Cambridge and London. The
Trust is sometimes accused of being a
cosy club. That may change this
summer with the arrival of its new
director, haematologist Mike Dexter,
a definite ‘outsider’ from Manchester.
And as to whether any women will
join the governors … who knows?
Does the Trust have special interests?
Sir Henry specified that the research
funded by his money was to include
veterinary and tropical medicine and
the history of medicine. Recently,
the governors took the decision to
support research on global
population issues and to put more
money into research in developing
countries. The Trust does not
normally support cancer research,
because so many others do.
How do ordinary researchers get their
hands on the money? Applications for
grants are competitive and assessed
by peer review, with about one in
three succeeding. Grants are made in
three areas: biomedical research
(which received £221 million in 1997);
the history of medicine; and science
communication (see
http://www.wellcome.ac.uk). The
governors take advice from expert
panels in four main subject areas:
infection and immunity; molecular
and cell biology; neurosciences; and
physiology and pharmacology. Most
support goes to researchers in the UK
and in the Republic of Ireland,
although there is nothing to stop the
Trust taking its money further afield.
So, what’s science communication?
The Wellcome Trust is keen on
communicating science to the
‘public’. It works with the great and
good of British science, such as
COPUS (the Committee on the
Public Understanding of Science), the
Science Museum and the Association
for Science Education, to make
science accessible to all. It also has its
own ‘Science for Life’ exhibition and
sponsors regular public debates, and
even the odd play, on topics such as
genetics and mental health.
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